A chitosan-mediated inhalable nanovaccine against SARS-CoV-2

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with several antigenic variants, has grown into a global challenge, and the rapid establishment of an immune barrier is crucial to achieving long-term control of the virus. This has led to a great demand for easy preparation and scalable...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuo, Shao-Hua, Wu, Jun-Jun, Zhao, Lang, Li, Wen-Hao, Zhao, Yu-Fen, Li, Yan-Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tsinghua University Press 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809230/
https://www.ncbi.nlm.nih.gov/pubmed/35126879
http://dx.doi.org/10.1007/s12274-021-4012-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809230/
https://www.ncbi.nlm.nih.gov/pubmed/35126879
http://dx.doi.org/10.1007/s12274-021-4012-9

Ejemplares similares